Loading the section…
The price of BioCryst Pharmaceuticals, Inc. (BCRX) on October 9, 2026 is 8.55 USD, +3.14% on the day. Over 52 weeks the stock traded between 6.00 USD and 11.22 USD; the price now sits 49% of the way up that range. Over the past year the price changed by +17.45%. Market capitalization is 2.17 billion USD, rank 29 among 128 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 2 November 2026 · Earnings calendar
Change over the period shown (line colour): +21.45 %
BioCryst Pharmaceuticals, Inc. trades on Nasdaq under the ticker BCRX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BCRX has traded between 6.00 $ and 11.22 $. As of 9 October 2026 the price stood 48.85 % of the way from the 52-week low to the high.
Over one year BCRX shares rose 17.45 %; over six months they fell 10.56 %. Volatility over 90 days is 47.06 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 2.5, below the sector median of 4.0. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 8.27 | 8.60 | 8.27 | 8.55 | 2M |
| 8 October 2026 | 8.36 | 8.40 | 8.13 | 8.29 | 5M |
| 7 October 2026 | 7.91 | 8.43 | 7.86 | 8.40 | 5M |
| 6 October 2026 | 8.15 | 8.15 | 7.87 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
BioCryst Pharmaceuticals, Inc. (BCRX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 885.7m $, net income was -458.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:4505 EMPEROR BOULEVARD SUITE 200, DURHAM, NC, 27703, US
BioCryst Pharmaceuticals, Inc. reported revenue of 886M $ and a net loss of 458M $ over the last four quarters. Net margin is −51.71 %. Revenue changed by +75.92 % year over year. Earnings per share are −1.77 $. Market capitalisation is 2.2B $.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 7.95 |
| 4M |
| 5 October 2026 | 8.17 | 8.25 | 7.92 | 8.10 | 5M |
| 2 October 2026 | 8.12 | 8.20 | 7.92 | 8.17 | 6M |
| 1 October 2026 | 8.30 | 8.38 | 8.07 | 8.12 | 7M |
| 30 September 2026 | 8.28 | 8.42 | 8.18 | 8.33 | 13M |
| 29 September 2026 | 8.42 | 8.50 | 8.22 | 8.27 | 5M |
| 28 September 2026 | 8.56 | 8.66 | 8.34 | 8.47 | 4M |
| 25 September 2026 | 8.52 | 8.63 | 8.40 | 8.59 | 4M |
| 24 September 2026 | 8.54 | 8.65 | 8.40 | 8.52 | 5M |
| 23 September 2026 | 8.75 | 8.86 | 8.46 | 8.57 | 4M |
| 22 September 2026 | 8.87 | 9.04 | 8.72 | 8.78 | 3M |
| 21 September 2026 | 8.75 | 8.85 | 8.58 | 8.76 | 3M |
| 18 September 2026 | 8.60 | 8.84 | 8.49 | 8.68 | 13M |
| 17 September 2026 | 8.54 | 8.73 | 8.43 | 8.70 | 5M |
| 16 September 2026 | 8.15 | 8.45 | 8.11 | 8.43 | 6M |
| 15 September 2026 | 8.19 | 8.23 | 8.02 | 8.16 | 6M |
| 14 September 2026 | 8.17 | 8.38 | 8.10 | 8.23 | 5M |